Eltanexor vs Selinexor

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Multiple Myeloma

Shared mechanism: XPO1 (exportin-1) · full Multiple Myeloma pipeline

Eltanexor

Developed by Karyopharm Therapeutics

Phase 1/2 in Multiple Myeloma
Weak signal

NCT02649790 · Phase 1/2 · completed

The study was nonrandomized, open-label, sequential, and had no comparator arm; its estimated enrollment was 277 participants across multiple cancer indications. Although it included clinical endpoints such as response, progression-free survival, and overall survival, no primary endpoint results are posted.

No aligned efficacy figure on record for this race.

Selinexor

Marketed by Karyopharm Therapeutics and partners

Approved in Multiple Myelomasmall molecule
Partial signal

NCT03110562 · Phase 3 · completed

The trial randomized 402 participants to selinexor-based therapy or an active bortezomib/dexamethasone control, but treatment was open-label rather than blinded. Its hard clinical primary endpoint, independent-reviewer progression-free survival, was met, with a median of 13.93 versus 9.46 months and p=0.0075; participants in the control arm could later cross over to selinexor treatment after progression.

Next expected readout: December 2026 · NCT06822972 (registry estimate)

Reported efficacy

SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd/Vd Arm: Progression-free Survival (PFS) as Assessed by Independent Review Committee (IRC) (From date of randomization until IRC-confirmed documented PD or death, censored date, whichever occurred first (up to 33 months)): SVd Arm: Selinexor + Bortezomib + Dexamethasone 13.93 Months vs Vd Arm: Bortezomib + Dexamethasone 9.46 Months (95% CI 8.11 to 10.78) (met)

Result source: NCT03110562

Results for Multiple Myeloma

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointEltanexorSelinexor
PFS, median—Not reported13.9 vs 9.5vs Bortezomib + Dexamethasonen 195NCT03110562
6 other results
OS, median—Not reported36.7 vs 32.8vs Bortezomib + Dexamethasonen 195NCT03110562
2 other results
ORR—Not reported76.4% vs 62.3%vs Bortezomib + Dexamethasonen 195NCT03110562
2 other results
VGPR or better—Not reported44.6% vs 32.4%vs Bortezomib + Dexamethasonen 195NCT03110562
MRD negativity—Not reported33.3%bwk 12 · n 3NCT02780609
3 other results
  • 16.7% wk 12 · n 6 · Phase 1/2 · secondary NCT02780609
  • 33.3% wk 12 · n 9 · Phase 1/2 · secondary NCT02780609
  • 100% wk 12 · n 2 · Phase 1/2 · secondary NCT02780609

PFS, median

Eltanexor
—Not reported
Selinexor
13.9 vs 9.5vs Bortezomib + Dexamethasonen 195NCT03110562
6 other results

OS, median

Eltanexor
—Not reported
Selinexor
36.7 vs 32.8vs Bortezomib + Dexamethasonen 195NCT03110562
2 other results

ORR

Eltanexor
—Not reported
Selinexor
76.4% vs 62.3%vs Bortezomib + Dexamethasonen 195NCT03110562
2 other results

VGPR or better

Eltanexor
—Not reported
Selinexor
44.6% vs 32.4%vs Bortezomib + Dexamethasonen 195NCT03110562

MRD negativity

Eltanexor
—Not reported
Selinexor
33.3%bwk 12 · n 3NCT02780609
3 other results
  • 16.7% wk 12 · n 6 · Phase 1/2 · secondary NCT02780609
  • 33.3% wk 12 · n 9 · Phase 1/2 · secondary NCT02780609
  • 100% wk 12 · n 2 · Phase 1/2 · secondary NCT02780609
  1. b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
  2. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  3. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Eltanexor: no structured comparison results are available for Multiple Myeloma.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. Eltanexor: 0 of 4 rows · Selinexor: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricSelinexor
Dropout rate
n/a: no completion milestoneSVd Arm: Selinexor + Bortezomib + a
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
show 9 more results
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
—SdX Arm: Selinexor + Dexamethasone
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
n/a: no completion milestonePart 1
NCT02336815 · Phase 2
n/a: no completion milestonePart 2
NCT02336815 · Phase 2
0%
NCT03944057 · Phase 2 · registry result, not featured evidence · combination
0%Phase 1 Level 1: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1 Level 2: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 1 Level 3: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
0%Phase 2: Selinexor Plus HDM HCT
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
Discontinued due to AEs
0.5%SVd Arm: Selinexor + Bortezomib + a
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
show 9 more results
—SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
—SdX Arm: Selinexor + Dexamethasone
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
22.8%Part 1
NCT02336815 · Phase 2
31.7%Part 2
NCT02336815 · Phase 2
—
NCT03944057 · Phase 2 · registry result, not featured evidence · combination
—Phase 1 Level 1: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1 Level 2: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 1 Level 3: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
—Phase 2: Selinexor Plus HDM HCT
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
Serious AEs
55.9%SVd Arm: Selinexor + Bortezomib + a
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
show 9 more results
42.4%SVdX Arm: Selinexor + Bortezomib +
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
50%SdX Arm: Selinexor + Dexamethasone
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
57%Part 1
NCT02336815 · Phase 2
63.4%Part 2
NCT02336815 · Phase 2
54.9%
NCT03944057 · Phase 2 · registry result, not featured evidence · combination
100%Phase 1 Level 1: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
66.7%Phase 1 Level 2: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
50%Phase 1 Level 3: Selinexor Plus HD
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
50%Phase 2: Selinexor Plus HDM HCT
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
Most frequent reported AEs
a
thrombocytopenia 61.5%
nausea 50.3%
fatigue 42.1%
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
show 9 more results
thrombocytopenia 50%
anaemia 45.5%
nausea 39.4%
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
weight decreased 42.9%
cough 28.6%
decreased appetite 28.6%
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
nausea 75.9%
thrombocytopenia 73.4%
fatigue 69.6%
NCT02336815 · Phase 2
thrombocytopenia 74%
nausea 71.5%
anaemia 65%
NCT02336815 · Phase 2
decreased platelet count 87.8%
anemia 86.6%
decreased white-cell count 82.9%
NCT03944057 · Phase 2 · registry result, not featured evidence · combination
febrile neutropenia 33.3%
nausea 33.3%
thromboembolic event 33.3%
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
febrile neutropenia 33.3%
hyperglycemia 33.3%
urinary tract infection 33.3%
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
diarrhea 33.3%
febrile neutropenia 33.3%
white blood cell decreased 33.3%
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination
platelet count decreased 100%
white blood cell decreased 100%
neutrophil count decreased 80%
NCT02780609 · Phase 1/2 · registry result, not featured evidence · combination

Notes

  1. aPopulation comparability has not been reviewed for 7 of these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

Selinexor

PFS 13.93 vs 9.46 Bortezomib + Dexamethasone months
time to event · months
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
show 2 more results
6.6 vs 8.84 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
3.88 vs 8.84 Bortezomib + Dexamethasone months
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 76.4% (n=195) vs 62.3% (n=207) Bortezomib + Dexamethasone
responder rate · % of participants
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
VGPR or Better 44.6% (n=195) vs 32.4% (n=207) Bortezomib + Dexamethasone
responder rate · % of participants
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
Overall Survival 36.67 vs 32.76 Bortezomib + Dexamethasone months
time to event · months
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response 17.28 vs 12.88 Bortezomib + Dexamethasone months
time to event · months
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
ORR 19% (n=63)
responder rate · % of participants
No placebo or comparator arm
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
show 1 more result
26.2% (n=122)
NCT02336815 · Phase 2
PFS 3.91 months
time to event · months
No placebo or comparator arm
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
show 3 more results
4.7 months
NCT02336815 · Phase 2
3.7 months
NCT02336815 · Phase 2
3.7 months
NCT03944057 · Phase 2 · registry result, not featured evidence · combination
Time to Next Treatment 16.13 vs 10.84 Bortezomib + Dexamethasone months
time to event · months
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
Time to Response 1.41 vs 1.61 Bortezomib + Dexamethasone months
time to event · months
NCT03110562 · Phase 3 · combination · Multiple Myeloma · phase 3
Duration of Response 6.2 months
time to event · months
No placebo or comparator arm
NCT02336815 · Phase 2
show 1 more result
4.4 months
NCT02336815 · Phase 2
Clinical Benefit 31.6% (n=79)
responder rate · % of participants
No placebo or comparator arm
NCT02336815 · Phase 2
show 1 more result
39.3% (n=122)
NCT02336815 · Phase 2
Duration of Clinical Benefit 5.6 months
time to event · months
No placebo or comparator arm
NCT02336815 · Phase 2
show 1 more result
3.8 months
NCT02336815 · Phase 2

+ 9 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Eltanexor's landscape · Selinexor's landscape